Healthcare of Ontario Pension Plan Trust Fund Grows Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 87,728 shares of the pharmaceutical company’s stock after purchasing an additional 3,882 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Vertex Pharmaceuticals were worth $39,772,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Swiss RE Ltd. purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $28,000. Eagle Bay Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $29,000. IMG Wealth Management Inc. increased its position in shares of Vertex Pharmaceuticals by 277.8% during the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 50 shares during the last quarter. Colonial Trust Co SC increased its position in shares of Vertex Pharmaceuticals by 118.8% during the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 38 shares during the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $33,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of VRTX opened at $444.92 on Monday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $507.92. The company has a 50 day simple moving average of $437.14 and a two-hundred day simple moving average of $452.53. The firm has a market cap of $112.92 billion, a P/E ratio of 26.39, a price-to-earnings-growth ratio of 1.90 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The business had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. During the same period last year, the firm posted $4.06 EPS. The company’s revenue was up 8.3% on a year-over-year basis. On average, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Royal Bank Of Canada upped their price target on shares of Vertex Pharmaceuticals from $541.00 to $543.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Canaccord Genuity Group reduced their target price on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a report on Tuesday, May 5th. Bank of America increased their target price on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, May 18th. Finally, Truist Financial began coverage on shares of Vertex Pharmaceuticals in a report on Wednesday, May 27th. They issued a “buy” rating and a $542.00 target price for the company. Twenty-two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $555.91.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 318 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $423.73, for a total transaction of $134,746.14. Following the completion of the sale, the director directly owned 4,924 shares of the company’s stock, valued at $2,086,446.52. This trade represents a 6.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 1,745 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $450.00, for a total transaction of $785,250.00. Following the sale, the chief marketing officer directly owned 21,015 shares of the company’s stock, valued at approximately $9,456,750. This trade represents a 7.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,133 shares of company stock valued at $4,973,106 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received bullish attention from market commentary highlighting that Wall Street remains interested in the stock despite a bearish “death cross” technical setup, suggesting investors are focusing more on the company’s fundamentals than the chart pattern. Article Title
• Positive Sentiment: The company announced new CASGEVY data at the European Hematology Association Congress, including the first European presentation of results in children ages 5–11 and additional global regulatory submissions, which could support longer-term growth for the gene-editing therapy. Article Title
• Positive Sentiment: Analysts and media coverage have been broadly upbeat on Vertex, including pieces describing it as a favored healthcare stock and a stock some investors view as attractive to buy now, reinforcing confidence in the name. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Vertex to $19.24 from $19.36, a small revision that may not materially change the long-term outlook but is a minor headwind for sentiment. Article Title
• Negative Sentiment: The stock has also experienced a recent pullback in some sessions, reflecting normal volatility and some profit-taking even as the broader narrative remains constructive. Article Title

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.